291 related articles for article (PubMed ID: 35963821)
21. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
22. Conjugate vaccine serotypes persist as major causes of non-invasive pneumococcal pneumonia in Portugal despite declines in serotypes 3 and 19A (2012-2015).
Horácio AN; Silva-Costa C; Lopes E; Ramirez M; Melo-Cristino J;
PLoS One; 2018; 13(11):e0206912. PubMed ID: 30388168
[TBL] [Abstract][Full Text] [Related]
23. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-A longitudinal study over 10 years based on public surveillance data in the Nordics.
Palmborg A; Skovdal M; Molden T; Åhman H; Chen L; Banefelt J
PLoS One; 2023; 18(6):e0287378. PubMed ID: 37363884
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study.
von Mollendorf C; Ulziibayar M; Gessner BD; Do LAH; Nguyen CD; Beavon R; Suuri B; Luvsantseren D; Narangerel D; Jenney A; Dunne EM; Satzke C; Darmaa B; Mungun T; Mulholland EK
BMC Public Health; 2021 Sep; 21(1):1731. PubMed ID: 34556065
[TBL] [Abstract][Full Text] [Related]
25. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
26. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
Ahmed SS; Lessa FC; Coradin H; Sánchez J; Carvalho MDG; Soda E; Peña C; Fernández J; Cedano D; Whitney CG; Feris-Iglesias J
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S228-S236. PubMed ID: 34469563
[TBL] [Abstract][Full Text] [Related]
27. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
[TBL] [Abstract][Full Text] [Related]
28. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
[TBL] [Abstract][Full Text] [Related]
29. Serotypes and antimicrobial resistance of
León ME; Samudio M; Kawabata A; Nagai M; Rojas L; Zárate N; Irala J; Leguizamón M; Gómez G; Ortellado J; Blasco R; Franco R; Chamorro G
J Med Microbiol; 2023 Jun; 72(6):. PubMed ID: 37289483
[No Abstract] [Full Text] [Related]
30. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay.
Pletz MW; Ewig S; Rohde G; Schuette H; Rupp J; Welte T; Suttorp N; Forstner C;
Vaccine; 2016 Apr; 34(20):2342-8. PubMed ID: 27016653
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of antimicrobial resistance in non-vaccine serotypes of non-invasive/colonization isolates of Streptococcus pneumoniae: A cross-sectional study eight years after the licensure of conjugate vaccine in Japan.
Kawaguchiya M; Urushibara N; Aung MS; Ito M; Takahashi A; Habadera S; Kobayashi N
J Infect Public Health; 2020 Aug; 13(8):1094-1100. PubMed ID: 32446777
[TBL] [Abstract][Full Text] [Related]
33. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.
Mackenzie GA; Hill PC; Sahito SM; Jeffries DJ; Hossain I; Bottomley C; Uchendu U; Ameh D; Ndiaye M; Osuorah CD; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Ahameefula E; Muhammad BS; Fombah AE; Saha D; Mackenzie R; Plumb I; Akano A; Ebruke B; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UNA; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Sowe D; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2017 Sep; 17(9):965-973. PubMed ID: 28601421
[TBL] [Abstract][Full Text] [Related]
34. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
[TBL] [Abstract][Full Text] [Related]
35. Impact of pneumococcal conjugate vaccine in children on the serotypic epidemiology of adult invasive pneumococcal diseases in Taiwan.
Chi HC; Hsieh YC; Tsai MH; Lee CH; Kuo KC; Huang CT; Huang YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):332-336. PubMed ID: 28082066
[TBL] [Abstract][Full Text] [Related]
36. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine.
Satzke C; Dunne EM; Choummanivong M; Ortika BD; Neal EFG; Pell CL; Nation ML; Fox KK; Nguyen CD; Gould KA; Hinds J; Chanthongthip A; Xeuatvongsa A; Mulholland EK; Sychareun V; Russell FM
Vaccine; 2019 Jan; 37(2):296-305. PubMed ID: 30502068
[TBL] [Abstract][Full Text] [Related]
37. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
[TBL] [Abstract][Full Text] [Related]
39. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
[TBL] [Abstract][Full Text] [Related]
40. Continued Vaccine Breakthrough Cases of Serotype 3 Complicated Pneumonia in Vaccinated Children, Portugal (2016-2019).
Silva-Costa C; Gomes-Silva J; Pinho MD; Friães A; Ramirez M; Melo-Cristino J
Microbiol Spectr; 2022 Aug; 10(4):e0107722. PubMed ID: 35862941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
